Significance of hyperhomocysteinemia

Clinical Laboratory

Volumn 52, Issue 7-8, 2006, Pages 367-374

  Herrmann, Wolfgang ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

B12; Chronic heart failure; Cognitive dysfunction; Coronary vessel disease; Folate; Homocysteine; Osteoporosis; Pregnancy complications; Renal disease; Stroke

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE; VITAMIN B GROUP;

ALZHEIMER DISEASE; CANADA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DATA ANALYSIS; DEGENERATIVE DISEASE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; ELDERLY CARE; FRAGILITY FRACTURE; GRAIN; HEART FAILURE; HUMAN; HYPERHOMOCYSTEINEMIA; MEDICAL RESEARCH; METHYLATION; MORTALITY; NEURAL TUBE DEFECT; OSTEOPOROSIS; PATHOPHYSIOLOGY; PREDICTION; PREGNANCY; PREGNANCY COMPLICATION; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SAMPLE SIZE; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME; UNITED STATES; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

AGE FACTORS; DNA METHYLATION; FEMALE; FOLIC ACID; HEART FAILURE, CONGESTIVE; HUMANS; HYPERHOMOCYSTEINEMIA; NEURODEGENERATIVE DISEASES; OSTEOPOROSIS; PREGNANCY; PREGNANCY COMPLICATIONS; RISK FACTORS; VITAMIN B 12;

EID: 33748349409     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Graham I.M., Daly L.E., Refsum H.M., Robinson K., Brattstrom L.E., Ueland P.M., Palma-Reis R.J., Boers G.H., Sheahan R.G., Israelsson B. et al. (1997). Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277: 1775-1781.
2. Boushey C.J., Beresford S.A., Omenn G.S., and Motulsky A.G. (1995). A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274: 1049-1057.
3. Wald D.S., Law M., and Morris J.K. (2002). Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325: 1202.
4. Herrmann W., Quast S., Ullrich M., Schultze H., Bodis M., and Geisel J. (1999). Hyperhomocysteinemia in high-aged subjects: relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutation. Atherosclerosis 144: 91-101.
5. Joosten E., Berg van-denA., Riezler R., Naurath H.J., Lindenbaum J., Stabler S.P., and Allen R.H. (1993). Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am. J. Clin. Nutr. 58: 468-476.
6. Naurath H.J., Joosten E., Riezler R., Stabler S.P., Allen R.H., and Lindenbaum J. (1995). Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 346: 85-89.
7. Beitz R., Mensink G.B., Fischer B., and Thamm M. (2002). Vitamins - dietary intake and intake from dietary supplements in Germany. Eur. J. Clin Nutr. 56: 539-545.
8. Selhub J., Jacques P.F., Wilson P.W., Rush D., and Rosenberg I.H. (1993). Vitamin status and intake as primary determinants of homocysteinemia in an elderly population [see comments]. JAMA 270: 2693-2698.
9. Herrmann W., Obeid R., Schorr H., and Geisel J. (2005). The usefulness of holotranscobalamin in predicting vitamin B12 status in different clinical settings. Curr. Drug Metab 6: 47-53.
10. Obeid R., Schorr H., Eckert R., and Herrmann W. (2004). Vitamin B12 status in the elderly as judged by available biochemical markers. Clin Chem 50: 238-241.
11. Herrmann W and Obeid R (2005). Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients. Clin Chem Lab Med 43: 1039-1047.
12. Herrmann W., Schorr H., Geisel J., and Riegel W. (2001). Homocysteine, cystathionine, methylmalonic acid and B-vitamins in patients with renal disease. Clin Chem Lab Med 39: 739-746.
13. van Guldener C, Stam F, and Stehouwer CDA (2005). Hyperhomocysteinemia in chronic kidney disease: focus on transmethylation. Clin Chem Lab Med 43: 1026-1031.
14. Herrmann W., Schorr H., Obeid R., Makowski J., Fowler B., and Kuhlmann M.K. (2005). Disturbed homocysteine and methionine cycle intermediates s-adenosylhomocysteine and s-adenosylmethionine are related to degree of renal insufficiency in type 2 diabetes. Clin Chem 51: 891-897.
15. Obeid R., Kuhlmann M.K., Kohler H., and Herrmann W. (2005). Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients. Clin Chem 51: 196-201.
16. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J., denHeijer M., Kluijtmans L.A., Heuvel van-denL.P. et al. (1995). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10: 111-113.
17. Herrmann W., Obeid R., Schorr H., Zarzour W., and Geisel J. (2003). Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism and the B-vitamins: a facet of nature-nurture interplay. Clin Chem Lab Med 41: 547-553.
18. Jacques P.F., Bostom A.G., Williams R.R., Ellison R.C., Eckfeldt J.H., Rosenberg I.H., Selhub J., and Rozen R. (1996). Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93: 7-9.
19. Klerk M., Verhoef P., Clarke R., Blom H.J., Kok F.J., and Schouten E.G. (2002). MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta- analysis. JAMA 288: 2023-2031.
20. Meleady R., Ueland P.M., Blom H., Whitehead A.S., Refsum H., Daly L.E., Vollset S.E., Donohue C., Giesendorf B., Graham I.M. et al. (2003). Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project. Am. J. Clin Nutr. 77: 63-70.
21. den Heijer M. (2000). Homocysteine and venous thrombosis. In: Homocysteine and vascular disease, Robinson K, ed. (Dordrecht, The Netherlands: Kluwer Academic Publishers), pp. 239-252.
22. Geisel J., Zimbelmann I, Schorr H., Knapp J.P., Bodis M., Hübner U., Georg T., and Herrmann W. (2001). Genetic defects as important factors for moderate hyperhomocysteinemia. Clin Chem Lab Med 39: 698-704.
23. Hoogeveen E.K., Kostense P.J., Beks P.J., Mackaay A.J., Jakobs C., Bouter L.M., Heine R.J., and Stehouwer C.D. (1998). Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler. Thromb. Vasc. Biol. 18:133-138.
24. Hoogeveen E.K., Kostense P.J., Jakobs C., Dekker J.M., Nijpels G., Heine R.J., Bouter L.M., and Stehouwer C.D. (2000). Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 101: 1506-1511.
25. Homocysteine Studies Collaboration (2002). Homocysteine and risk of ischemic heart disease and stroke: a meta- analysis. JAMA 288: 2015-2022.
26. Vitamin Treatment Trialist's Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006 Feb;151(2):282-7.
27. Toole J.F., Malinow M.R., Chambless L.E., Spence J.D., Pettigrew L.C., Howard V.J., Sides E.G., Wang C.H., and Stampfer M. (2004). Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291: 565-575.
28. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, and Rasmussen K. NORVIT Trial Investigators (2006). Homocysteine lowering and cardiovascular events after acute myocardial infarction.N Engl J Med 354:1578-88.
29. Spence J.D., Bang H., Chambless L.E., and Stampfer M.J. (2005). Vitamin Intervention For Stroke Prevention trial: an efficacy analysis. Stroke 36: 2404-2409.
30. The Heart Outcome Prevention Evaluation (HOPE) 2 Investigators (2006). Homocysteine lowering with folic acid and B-vitamins in vascular disease. N Engl J Med 354:1567-77
31. Schnyder G., Roffi M., Pin R., Hammer Y., Lange H., Eberli F.R., Meier B., Turi Z.G., and Hess O.M. (2001). Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N. Engl. J. Med 345: 1593-1600.
32. Lange H., Suryapranata H., De L.G., Burner C., Dille J., Kallmayer K., Pasalary M.N., Scherer E., and Dambrink J.H. (2004). Folate therapy and in-stent restenosis after coronary stenting. N. Engl. J. Med 350: 2673-2681.
33. Yang Q., Botto L.D., Erickson J.D., Berry R.J., Sambell C., Johansen H., and Friedman J.M. (2006). Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 113: 1335-1343.
34. Blacher J., Demuth K., Guerin A.P., Vadez C., Moatti N., Safar M.E., and London G.M. (1999). Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J. Nephrol. 12: 248-255.
35. Ventura P., Panini R., Verlato C., Scarpetta G., and Salvioli G. (2001). Hyperhomocysteinemia and related factors in 600 hospitalized elderly subjects. Metabolism 50: 1466-1471.
36. Vasan R.S., Beiser A., D'Agostino R.B., Levy D., Selhub J., Jacques P.F., Rosenberg I.H., and Wilson P.W. (2003). Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 289: 1251-1257.
37. Herrmann M., Kindermann I., Muller S., Georg T., Kindermann M., Bohm M., and Herrmann W. (2005). Relationship of plasma homocysteine with the severity of chronic heart failure. Clin Chem 51: 1512-1515.
38. Witte KK, Nikitin NP, Parker AC, von Haehling S, Anker SD, Clark AL, Cleland JG. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J. 2005 Nov; 26(21):2238-44
39. Roger V.L., Weston S.A., Redfield M.M., Hellermann-Homan J.P., Killian J., Yawn B.P., and Jacobsen S.J. (2004). Trends in heart failure incidence and survival in a community-based population. JAMA 292: 344-350.
40. Herzlich B.C., Lichstein E., Schulhoff N., Weinstock M., Pagala M., Ravindran K., Namba T., Nieto F.J., Stabler S.P., Allen R.H. et al. (1996). Relationship among homocyst(e)ine, vitamin B-12 and cardiac disease in the elderly: association between vitamin B-12 deficiency and decreased left ventricular ejection fraction. J. Nutr. 126: 1249S-1253S.
41. McKusick V.A. (1966). Heritable disorders of connective tissue. (St. Louis: C.V. Mosby), 155pp.
42. Parrot F., Redonnet-Vernhet I, Lacombe D., and Gin H. (2000). Osteoporosis in late-diagnosed adult homocystinuric patients. J. Inherit. Metab Dis. 23: 338-340.
43. van Meurs J.B., Dhonukshe-Rutten R.A., Pluijm S.M., van der K.M., de J.R., Lindemans J., de Grout L.C., Hofman A., Witteman J.C., van Leeuwen J.P. et al. (2004). Homocysteine levels and the risk of osteoporotic fracture. N. Engl. J Med 350: 2033-2041.
44. McLean R.R., Karasik D., Selhub J., Tucker K.L., Ordovas J.M., Russo G.T., Cupples L.A., Jacques P.F., and Kiel D.P. (2004). Association of a common polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene with bone phenotypes depends on plasma folate status. J. Bone Miner. Res. 19: 410-418.
45. Herrmann M., Kraenzlin M., Pape G., Sand-Hill M., and Herrmann W. (2005). Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women. Clin Chem Lab Med 43: 1118-1123.
46. Cagnacci A., Baldassari F., Rivolta G., Arangino S., and Volpe A. (2003). Relation of homocysteine, folate, and vitamin B12 to bone mineral density of postmenopausal women. Bone 33: 956-959.
47. Dhonukshe-Rutten R.A., Pluijm S.M., de Groot L.C., Lips P., Smit J.H., and van Staveren W.A. (2005). Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner. Res. 20: 921-929.
48. Sato Y., Honda Y., Iwamoto J., Kanoko T., and Satoh K. (2005). Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. JAMA 293: 1082-1088.
49. [161] 43 van Meurs J.B., Dhonukshe-Rutten R.A., Pluijm S.M., van der K.M., de J.R., Lindemans J., de Groot L.C., Hofman A., Witteman J.C., van Leeuwen J.P. et al. (2004). Homocysteine levels and the risk of osteoporotic fracture. N. Engl. J Med 350: 2033-2041.
50. Nurk E., Refsum H., Tell G.S., Engedal K., Vollset S.E., Ueland P.M., Nygaard H.A., and Smith A.D. (2005). Plasma total homocysteine and memory in the elderly: The Hordaland Homocysteine study. Ann. Neurol. 58: 847-857.
51. Sachdev P.S. (2005). Homocysteine and brain atrophy. Prog. Neuropsychopharmacol. Biol. Psychiatry 29: 1152-1161.
52. Bjelland I., Tell G.S., Vollset S.E., Refsum H., and Ueland P.M. (2003). Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch. Gen. Psychiatry 60: 618-626.
53. Penninx B.W., Guralnik J.M., Ferrucci L., Fried L.P., Allen R.H., and Stabler S.P. (2000). Vitamin B(12) deficiency and depression in physically disabled older women: epidemiologic evidence from the Women's Health and Aging Study. Am. J Psychiatry 157: 715-721.
54. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., Wilson P.W., and Wolf P.A. (2002). Plasma homocysteine as a risk factor for dementia and Alzheimers disease. N. Engl. J. Med 346: 476-483.
55. Wright C.B., Lee H.S., Paik M.C., Stabler S.P., Allen R.H., and Sacco R.L. (2004). Total homocysteine and cognition in a triethnic cohort: the Northern Manhattan Study. Neurology 63: 254-260.
56. Riggs K.M., Spiro A., III, Tucker K., and Rush D. (1996). Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am. J Clin Nutr. 63: 306-314.
57. Tucker K.L., Qiao N., Scott T., Rosenberg I., and Spiro A., III (2005). High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. Am. J Clin Nutr. 82: 627-635.
58. Nilsson K., Gustafson L., and Hultberg B. (2002). Relation between plasma homocysteine and Alzheimers disease. Dement. Geriatr. Cogn Disord. 14: 7-12.
59. Clarke R., Smith A.D., Jobst K.A., Refsum H., Sutton L., and Ueland P.M. (1998). Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol. 55: 1449-1455.
60. McCaddon A., Davies G., Hudson P., Tandy S., and Cattell H. (1998). Total serum homocysteine in senile dementia of Alzheimer type. Int. J. Geriatr. Psychiatry 13: 235-239.
61. Quadri P., Fragiacomo C., Pezzati R., Zanda E., Forloni G., Tettamanti M., and Lucca U. (2004). Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am. J Clin Nutr. 80:114-122.
62. Herrmann W, Isber S, Obeid R, Herrmann M, Jouma M. (2005). Concentrations of homocysteine. related metabolites and asymmetric dimethylarginine in preeclamptic women with poor nutritional status. Clin Chem Lab Med;43:1139-1146.
63. Vollset S.E., Refsum H., Irgens L.M., Emblem B.M., Tverdal A., Gjessing H.K., Monsen A.L., and Ueland P.M. (2000). Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine Study. Am. J. Clin Nutr. 71: 962-968.
64. Christensen B., Arbour L., Tran P., Leclerc D., Sabbaghian N., Platt R., Gilfix B.M., Rosenblatt D.S., Gravel R.A., Forbes P. et al. (1999). Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am. J Med Genet. 84:151-157.
65. Williams L.J., Mai C.T., Edmonds L.D., Shaw G.M., Kirby R.S., Hobbs C.A., Sever L.E., Miller L.A., Meaney F.J., and Levitt M. (2002). Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology 66: 33-39.
66. Blom HJ, Afman L.A., van der Linden I, and den Heijer H. (2005). Vitamin B12 insufficiency and the risk of fetal neural tube defects. Clin Chem Lab Med;43(3):A3.
67. Murphy M.M., Scott J.M., Arija V., Molloy A.M., and Fernandez-Ballart J.D. (2004). Maternal homocysteine before conception and throughout pregnancy predicts fetal homocysteine and birth weight. Clin Chem 50: 1406-1412.
68. Weir D.G. and Scott J.M. (1999). Brain function in the elderly: role of vitamin B12 and folate. Br. Med. Bull. 55: 669-682.
69. Scarpa S., Fuso A., D'Anselmi F., and Cavallaro R.A. (2003). Presenilin 1 gene silencing by S-adenosylmethionine: a treatment for Alzheimer disease? FEBS Lett. 541: 145-148.
70. Friso S. and Choi S.W. (2005). The potential cocarcinogenic effect of vitamin B12 deficiency. Clin Chem Lab Med 43: 1158-1163.
71. Ingrosso D., Cimmino A., Perna A.F., Masella L., De Santo N.G., De Bonis M.L., Vacca M., D'Esposito M., D'Urso M., Galletti P. et al. (2003). Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 361: 1693-1699.
72. Geisel J., Schorr H., Bodis M., Isber S., Hubner U., Knapp J.P., Obeid R., and Herrmann W. (2005). The vegetarian lifestyle and DNA methylation. Clin Chem Lab Med 43: 1164-1169.